Refractory Minimal Change Disease and Focal Segmental Glomerular Sclerosis Treated With Anakinra

doi:10.1016/j.ekir.2021.10.018

Case Reports

. 2021 Oct 30;7(1):121-124.

doi: 10.1016/j.ekir.2021.10.018. eCollection 2022 Jan.

Refractory Minimal Change Disease and Focal Segmental Glomerular Sclerosis Treated With Anakinra

Affiliations

¹ Division of Nephrology, Dialysis, and Transplantation, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Giannina Gaslini, Genova, Italy.
² Laboratory of Molecular Nephrology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Giannina Gaslini, Genova, Italy.
³ Renal Division, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

PMID: 35005321
PMCID: PMC8720665
DOI: 10.1016/j.ekir.2021.10.018

Case Reports

Refractory Minimal Change Disease and Focal Segmental Glomerular Sclerosis Treated With Anakinra

Andrea Angeletti et al. Kidney Int Rep. 2021.

. 2021 Oct 30;7(1):121-124.

doi: 10.1016/j.ekir.2021.10.018. eCollection 2022 Jan.

Authors

Affiliations

¹ Division of Nephrology, Dialysis, and Transplantation, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Giannina Gaslini, Genova, Italy.
² Laboratory of Molecular Nephrology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Giannina Gaslini, Genova, Italy.
³ Renal Division, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

PMID: 35005321
PMCID: PMC8720665
DOI: 10.1016/j.ekir.2021.10.018

No abstract available

PubMed Disclaimer

Figures

**Figure 1**
Proteinuria and serum creatinine levels in a patient with focal segmental glomerular sclerosis multidrug resistant. h, hour; HD, hemodialysis; IL-1R, interleukin-1 receptor; pCreat, creatinine in patient.

See this image and copyright information in PMC

Cited by

Biologics in steroid resistant nephrotic syndrome in childhood: review and new hypothesis-driven treatment.
Angeletti A, Bruschi M, Kajana X, La Porta E, Spinelli S, Caridi G, Lugani F, Verrina EE, Ghiggeri GM. Angeletti A, et al. Front Immunol. 2023 Aug 29;14:1213203. doi: 10.3389/fimmu.2023.1213203. eCollection 2023. Front Immunol. 2023. PMID: 37705972 Free PMC article. Review.
To biopsy or not to biopsy a teenager with idiopathic nephrotic syndrome? Biopsy first.
Bigatti C, Chiarenza DS, Angeletti A. Bigatti C, et al. Pediatr Nephrol. 2025 Feb;40(2):571-578. doi: 10.1007/s00467-024-06510-6. Epub 2024 Sep 9. Pediatr Nephrol. 2025. PMID: 39251432 Free PMC article.
Anti-Tumor Necrosis Factor Treatment for Glomerulopathy: Case Report and Review of Literature.
Jones OY, Malone LC, Brunson C. Jones OY, et al. Fed Pract. 2024 Aug;41(8):250-255. doi: 10.12788/fp.0506. Epub 2024 Aug 15. Fed Pract. 2024. PMID: 39410922 Free PMC article.
State of the art in childhood nephrotic syndrome: concrete discoveries and unmet needs.
Vincenti F, Angeletti A, Ghiggeri GM. Vincenti F, et al. Front Immunol. 2023 Jul 12;14:1167741. doi: 10.3389/fimmu.2023.1167741. eCollection 2023. Front Immunol. 2023. PMID: 37503337 Free PMC article. Review.
Editorial: The kidney in auto-immune and auto-inflammatory processes: Definitions, mechanisms, and biomarkers.
Vaglio A, Gattorno M, McAdoo S, Obici LP, Ghiggeri GM. Vaglio A, et al. Front Med (Lausanne). 2023 Jan 10;9:1129021. doi: 10.3389/fmed.2022.1129021. eCollection 2022. Front Med (Lausanne). 2023. PMID: 36703882 Free PMC article. No abstract available.

References

1. Kitiyakara C., Kopp J.B., Eggers P. Trends in the epidemiology of focal segmental glomerulosclerosis. Semin Nephrol. 2003;23:172–182. doi: 10.1053/snep.2003.50025. - DOI - PubMed
1. Trautmann A., Bodria M., Ozaltin F., et al. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. Clin J Am Soc Nephrol. 2015;10:592–600. doi: 10.2215/CJN.06260614. - DOI - PMC - PubMed
1. Iijima K., Sako M., Nozu K., et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384:1273–1281. doi: 10.1016/S0140-6736(14)60541-9. - DOI - PubMed
1. Ravani P., Bonanni A., Ghiggeri G.M. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol. BMJ Open. 2017;7 doi: 10.1136/bmjopen-2016-013319. - DOI - PMC - PubMed
1. Ravani P., Lugani F., Drovandi S., et al. Rituximab vs low-dose mycophenolate mofetil in recurrence of steroid-dependent nephrotic syndrome in children and young adults: a randomized clinical trial. JAMA Pediatr. 2021;175:631–632. doi: 10.1001/jamapediatrics.2020.6150. - DOI - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

[1] Kitiyakara C., Kopp J.B., Eggers P. Trends in the epidemiology of focal segmental glomerulosclerosis. Semin Nephrol. 2003;23:172–182. doi: 10.1053/snep.2003.50025. - DOI - PubMed

[2] Kitiyakara C., Kopp J.B., Eggers P. Trends in the epidemiology of focal segmental glomerulosclerosis. Semin Nephrol. 2003;23:172–182. doi: 10.1053/snep.2003.50025. - DOI - PubMed

[3] Trautmann A., Bodria M., Ozaltin F., et al. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. Clin J Am Soc Nephrol. 2015;10:592–600. doi: 10.2215/CJN.06260614. - DOI - PMC - PubMed

[4] Trautmann A., Bodria M., Ozaltin F., et al. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. Clin J Am Soc Nephrol. 2015;10:592–600. doi: 10.2215/CJN.06260614. - DOI - PMC - PubMed

[5] Iijima K., Sako M., Nozu K., et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384:1273–1281. doi: 10.1016/S0140-6736(14)60541-9. - DOI - PubMed

[6] Iijima K., Sako M., Nozu K., et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384:1273–1281. doi: 10.1016/S0140-6736(14)60541-9. - DOI - PubMed

[7] Ravani P., Bonanni A., Ghiggeri G.M. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol. BMJ Open. 2017;7 doi: 10.1136/bmjopen-2016-013319. - DOI - PMC - PubMed

[8] Ravani P., Bonanni A., Ghiggeri G.M. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol. BMJ Open. 2017;7 doi: 10.1136/bmjopen-2016-013319. - DOI - PMC - PubMed

[9] Ravani P., Lugani F., Drovandi S., et al. Rituximab vs low-dose mycophenolate mofetil in recurrence of steroid-dependent nephrotic syndrome in children and young adults: a randomized clinical trial. JAMA Pediatr. 2021;175:631–632. doi: 10.1001/jamapediatrics.2020.6150. - DOI - PMC - PubMed

[10] Ravani P., Lugani F., Drovandi S., et al. Rituximab vs low-dose mycophenolate mofetil in recurrence of steroid-dependent nephrotic syndrome in children and young adults: a randomized clinical trial. JAMA Pediatr. 2021;175:631–632. doi: 10.1001/jamapediatrics.2020.6150. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Refractory Minimal Change Disease and Focal Segmental Glomerular Sclerosis Treated With Anakinra

Affiliations

Refractory Minimal Change Disease and Focal Segmental Glomerular Sclerosis Treated With Anakinra

Authors

Affiliations

Figures

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources